ABSTRACT. The aim of this study was to explore the relationship between 2 genetic polymorphisms of the methylenetetrahydrofolate reductase gene (MTHFR), C677T and A1298C, and determine the long-term reproductive outcome in infertile men. This was a prospective study conducted in an andrology clinic. Men with a 1-year history of infertility were assessed for the MTHFR polymorphisms at a 5-year follow-up. We compared the MTHFR C677T and A1298C polymorphisms by polymerase chain reaction-restriction fragment length polymorphism between men who did and did not bear children during follow-up. Of the 215 men who were infertile at 1 year, 82 (38.1%) remained infertile and 133 (61.9%) achieved natural conception during the 5-year follow-up, with the highest rate in the first year (32.6%). The MTHFR 677TT genotype (homozygote) was associated with a substantially increased risk of infertility during follow-up [odds (2014) ratio (OR) = 10.242; 95% confidence interval (CI) = 1.257-83.464] relative to the MTHFR 677CC genotype (wild-type). Risk of infertility was not increased by the MTHFR A1298C polymorphism alone, but was increased by the combination of polymorphisms MTHFR C677T and MTHFR A1298C (OR = 11.818; 95%CI = 1.415-98.674). The homozygous MTHFR C677T genotype was a risk factor for male infertility during 5-year follow-up, whereas a correlation between MTHFR A1298C and infertility was not observed. The MTHFR C677T and MTHFR A1298C polymorphisms had additive effects on male infertility.

No abstract

Short oral presentation abstractswere to determine rates of success, predictors for success and explore complications. Methods: Retrospective analysis of pathology reports and patients charts in 64 consecutive patients in the period from October 2014-January 2018 in a gynecological oncology centre. A 18-gauge trucut needle was used in all cases. Rates of success and complications were calculated. Gold standard was final histology from surgery, except in cases of ovarian cancer, where chemotherapy was initiated after positive histology. Two patients had no gold standard and the biopsies were considered insufficient. Results: 64 patients had a total of 67 biopsies. Indications for biopsies were suspicion of ovarian cancer (n=39), uterine sarcoma (n=14), metastasis from gastrointestinal cancer (n=5), peritoneal cancer (n=4) and other pelvic cancer (n=2). Age range 22-90, median 58. In 80 % of the patients (51/64) the biopsies were sufficient for diagnosis. The failures were not operator or time associated. Success rate was related to indication, among patients with suspicion of ovarian cancer the success rate was 85% (33/49), but in sarcoma the success rate was 65% (9/14) (p=0.0011 (Fisher's exact test)). Recurrent biopsies in three patients with primarily insufficient biopsy led only to diagnosis in one. One patient, 1.6% (1/64) had a pulmonary embolism after the anticoagulant therapy was paused in accordance with National guidelines. Conclusions: Transvaginal ultrasound-guided trucut biopsies were successful in 80% of patients. The success rate was related to indication with a significant higher success rate in ovarian cancer 83% compared to 60% in uterine sarcoma. The complication rate was 1.6%. OP08.09Gastrointestinal stromal tumour presenting as pelvic masses